AMRX (Amneal Pharmaceuticals) Short Interest


AMRX Amneal Pharmaceuticals Inc AMRX
63 GF Score
Price $17.24
GF Value $7.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AMRX vs INDV, KNSA, LQDA: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amneal Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Short Interest falls into.


AMRX
63GF Score
Amneal Pharmaceuticals Inc AMRX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.24 is trading 127.7% above its estimated GF Value™ of $7.57. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Short Interest:
  • GF Value™: $7.57 vs. price of $17.24 (127.7% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for AMRX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.24
Price
$7.57
GF Value